DNA-Damage-Response-Targeting Mitochondria-Activated Multifunctional Prodrug Strategy for Self-Defensive Tumor Therapy

Angew Chem Int Ed Engl. 2022 Apr 11;61(16):e202117075. doi: 10.1002/anie.202117075. Epub 2022 Feb 19.

Abstract

We report a novel multifunctional construct, M1, designed explicitly to target the DNA damage response in cancer cells. M1 contains both a floxuridine (FUDR) and protein phosphatase 2A (PP2A) inhibitor combined with a GSH-sensitive linker. Further conjugation of the triphenylphosphonium moiety allows M1 to undergo specific activation in the mitochondria, where mitochondria-mediated apoptosis is observed. Moreover, M1 has enormous effects on genomic DNA ascribed to FUDR's primary function of impeding DNA/RNA synthesis combined with diminishing PP2A-activated DNA repair pathways. Importantly, mechanistic studies highlight the PP2A obtrusion in FUDR/5-fluorouracil (5-FU) therapy and underscore the importance of its inhibition to harbor therapeutic potential. HCT116 cell xenograft-bearing mice that have a low response rate to 5-FU show a prominent effect with M1, emphasizing the importance of DNA damage response targeting strategies using tumor-specific microenvironment-activatable systems.

Keywords: DNA Damage Response; DNA Repair; Drug Delivery; Floxuridine; Protein Phosphatase 2A.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Line, Tumor
  • DNA
  • Floxuridine / pharmacology
  • Floxuridine / therapeutic use
  • Fluorouracil / pharmacology
  • Fluorouracil / therapeutic use
  • Humans
  • Mice
  • Mitochondria
  • Prodrugs* / pharmacology
  • Prodrugs* / therapeutic use

Substances

  • Prodrugs
  • Floxuridine
  • DNA
  • Fluorouracil